4D Molecular Therapeutics (FDMT) Equity Average (2020 - 2025)
4D Molecular Therapeutics (FDMT) has disclosed Equity Average for 6 consecutive years, with $394.9 million as the latest value for Q3 2025.
- On a quarterly basis, Equity Average fell 30.79% to $394.9 million in Q3 2025 year-over-year; TTM through Sep 2025 was $394.9 million, a 30.79% decrease, with the full-year FY2024 number at $409.2 million, up 51.8% from a year prior.
- Equity Average was $394.9 million for Q3 2025 at 4D Molecular Therapeutics, down from $445.3 million in the prior quarter.
- In the past five years, Equity Average ranged from a high of $594.5 million in Q2 2024 to a low of $225.0 million in Q1 2023.
- A 5-year average of $353.4 million and a median of $307.6 million in 2022 define the central range for Equity Average.
- Peak YoY movement for Equity Average: skyrocketed 415.68% in 2021, then tumbled 30.79% in 2025.
- 4D Molecular Therapeutics' Equity Average stood at $271.6 million in 2021, then decreased by 11.13% to $241.4 million in 2022, then surged by 32.1% to $318.9 million in 2023, then skyrocketed by 66.76% to $531.8 million in 2024, then fell by 25.73% to $394.9 million in 2025.
- Per Business Quant, the three most recent readings for FDMT's Equity Average are $394.9 million (Q3 2025), $445.3 million (Q2 2025), and $490.2 million (Q1 2025).